Neurofibromatosis type 1
Zuletzt aktualisiert 20 Apr 2021
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Neurofibromatosis type 1 is a condition characterised by changes in skin coloring (pigmentation) and the growth of tumours along nerves in the skin, brain, and other parts of the body. The signs and symptoms of this condition vary widely among affected people.
Beschreibung
Neurofibromatosis type 1 is a condition characterised by changes in skin coloring (pigmentation) and the growth of tumours along nerves in the skin, brain, and other parts of the body. The signs and symptoms of this condition vary widely among affected people.
Beginning in early childhood, almost all people with neurofibromatosis type 1 have multiple café-au-lait spots, which are flat patches on the skin that are darker than the surrounding area. These spots increase in size and number as the individual grows older. Freckles in the underarms and groin typically develop later in childhood.
Most adults with neurofibromatosis type 1 develop neurofibromas, which are noncancerous (benign) tumours that are usually located on or just under the skin. These tumours may also occur in nerves near the spinal cord or along nerves elsewhere in the body. Some people with neurofibromatosis type 1 develop cancerous tumours that grow along nerves. These tumours, which usually develop in adolescence or adulthood, are called malignant peripheral nerve sheath tumours. People with neurofibromatosis type 1 also have an increased risk of developing other cancers, including brain tumours and cancer of blood-forming tissue (leukemia).
During childhood, benign growths called Lisch nodules often appear in the colored part of the eye (the iris). Lisch nodules do not interfere with vision. Some affected individuals also develop tumours that grow along the nerve leading from the eye to the brain (the optic nerve). These tumours, which are called optic gliomas, may lead to reduced vision or total vision loss. In some cases, optic gliomas have no effect on vision.
Additional signs and symptoms of neurofibromatosis type 1 vary, but they can include high blood pressure (hypertension), short stature, an unusually large head (macrocephaly), and skeletal abnormalities such as an abnormal curvature of the spine (scoliosis). Although most people with neurofibromatosis type 1 have normal intelligence, learning disabilities and attention-deficit/hyperactivity disorder (ADHD) occur frequently in affected individuals.
Inheritance patterns
The source lists the following possible inheritance patterns: Autosomal dominant. More than one pattern can apply in different cases.
Related genes
Other names
Neurofibromatosis 1
NF1
Peripheral neurofibromatosis
Recklinghausen disease, nerve
Von Recklinghausen disease
Related patient information and medicines

Patient information leaflet
Gehirntumore
This leaflet aims to give a brief overview of the various types of brain tumours. The treatment and survival rates... Genetic factors may be a risk for some people - perhaps in about 1 in 20 cases. For example, people with the hereditary diseases genannt neurofibromatosis type 1, Turcot's syndrome, Li-Fraumeni cancer syndrome, and tuberous.

Patient information leaflet
Planung, schwanger zu werden
You should have access to details about who you ... Hereditary conditions People with a history of a condition that runs in families may wish to have genetic testing before planning a pregnancy. This will help assess the chances of having that condition. Examples of conditions which may run in families include: Huntington's disease..

Patient information leaflet
Rhabdomyosarkom
A rhabdomyosarcoma ist a type of soft tissue sarcoma. Rhabdomyosarcomas grow in the muscles of the body. ... The exact causes of rhabdomyosarcomas are unknown. Rhabdomyosarcomas are slightly more common in children with certain genetic disorders such as Neurofibromatose oder Li-Fraumeni syndrome. Soft tissue sarcomas may occur in an area that has.

Patient information leaflet
Skoliose und Kyphose
Scoliosis is a back condition that causes the (back) spine to curve to the side - either left or right. Most cases develop in children between the ages of 9 and 14 years during the growth spurt of puberty. This means the curve is caused by a condition which affects muscles or nerves of the back. For example, it may happen in some people with.

Patient information leaflet
Epilepsie
About 1 in 30 people in the UK develop epilepsy at some stage in their lives. It most commonly starts in childhood and in people aged over 60. Examples of these rare genet... Fragile X syndrome. Rett syndrome. Neurofibromatosis. Dravet syndrome. Structural epilepsy Structural epilepsy is caused by damage or changes in the brain's structure, which.

Patient information leaflet
Akustikusneurinom
Ein Akustikusneurinom is a rare non-cancerous tumour in the brain. The tumour grows on a nerve in the brain near to the ear. There are many... Acoustic neuroma causes The cause of most acoustic neuromas is unknown. In fewer than 1 in 10 people, an acoustic neuroma is caused by neurofibromatosis type 2 (NF2). NF2 ist a very rare genetic disorder that.
Weiterführende Lektüre und Referenzen
- Neurofibromatosis type 1; MedlinePlus, National Library of Medicine.
- Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol. 2004 Apr;17(2):101-5. doi: 10.1097/00019052-200404000-00004.
- Baralle D, Mattocks C, Kalidas K, Elmslie F, Whittaker J, Lees M, Ragge N, Patton MA, Winter RM, ffrench-Constant C. Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS). Am J Med Genet A. 2003 May 15;119A(1):1-8. doi: 10.1002/ajmg.a.20023.
- De Luca A, Bottillo I, Sarkozy A, Carta C, Neri C, Bellacchio E, Schirinzi A, Conti E, Zampino G, Battaglia A, Majore S, Rinaldi MM, Carella M, Marino B, Pizzuti A, Digilio MC, Tartaglia M, Dallapiccola B. NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet. 2005 Dec;77(6):1092-101. doi: 10.1086/498454. Epub 2005 Oct 26.
- Friedman JM. Neurofibromatosis 1. 1998 Oct 2 [updated 2025 Apr 3]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1109/
- Hart L. Primary care for patients with neurofibromatosis 1. Nurse Pract. 2005 Jun;30(6):38-43. doi: 10.1097/00006205-200506000-00007. No abstract available.
- Huffmeier U, Zenker M, Hoyer J, Fahsold R, Rauch A. A variable combination of features of Noonan syndrome and neurofibromatosis type I are caused by mutations in the NF1 gene. Am J Med Genet A. 2006 Dec 15;140(24):2749-56. doi: 10.1002/ajmg.a.31547.
- Kandt RS. Tuberous sclerosis complex and neurofibromatosis type 1: the two most common neurocutaneous diseases. Neurol Clin. 2003 Nov;21(4):983-1004. doi: 10.1016/s0733-8619(03)00004-5.
- Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE. Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol. 2006 Mar;13(1):8-20. doi: 10.1016/j.spen.2006.01.006.
- Reynolds RM, Browning GG, Nawroz I, Campbell IW. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet. 2003 May 3;361(9368):1552-4. doi: 10.1016/s0140-6736(03)13166-2. No abstract available.
- Rose VM. Neurocutaneous syndromes. Mo Med. 2004 Mar-Apr;101(2):112-6.
- Theos A, Korf BR; American College of Physicians; American Physiological Society. Pathophysiology of neurofibromatosis type 1. Ann Intern Med. 2006 Jun 6;144(11):842-9. doi: 10.7326/0003-4819-144-11-200606060-00010. No abstract available.
- Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol. 2006 Mar;13(1):2-7. doi: 10.1016/j.spen.2006.01.005.
- Ward BA, Gutmann DH. Neurofibromatosis 1: from lab bench to clinic. Pediatr Neurol. 2005 Apr;32(4):221-8. doi: 10.1016/j.pediatrneurol.2004.11.002.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
20 Apr 2021 | Neueste Version
1 Mar 2007 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.

Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.